Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basket Trial of Ixekizumab in Autoimmune Inflammatory Skin Diseases
ChiCTR2200059272Phase 2Not yet recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixekizumab in pityriasis rubra pilaris (PRP), hidradenitis suppurativa (HS), Netherton syndrome (NS) and 2 more (2 cohorts), sponsored by Southern Medical University Dermatology Hospital. Primary endpoints: Psoriasis Area and Severity Index (PASI), Hidradenitis Suppurativa Lesion Area and Severity Index (HS-LASI) and 2 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
ixekizumab
03
Conditions
pityriasis rubra pilaris (PRP)hidradenitis suppurativa (HS)Netherton syndrome (NS)Erythrokeratoderma variabilis (EKV)progressive symmetrical erythrokeratoderma (PSEK)
Beyond the preview
Go deeper on ChiCTR2200059272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059272.